Active elimination of the marine biotoxin okadaic acid by P-glycoprotein through an in vitro gastrointestinal barrier

Toxicology Letters

Volumn 225, Issue 2, 2014, Pages 311-317

  Ehlers, Anke ^a   These, Anja ^a   Hessel, Stefanie ^a   Preiss Weigert, Angelika ^a   Lampen, Alfonso ^a  

^a FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

Author keywords

Caco 2 model; Detoxification; Marine biotoxin; MDCK II; Okadaic acid; P glycoprotein

Indexed keywords

ABC TRANSPORTER; FLUORESCEIN SODIUM; MULTIDRUG RESISTANCE PROTEIN; OKADAIC ACID;

ACTIVE TRANSPORT; ANIMAL CELL; ARTICLE; BIOAVAILABILITY; CONTAMINATED SHELLFISH; CONTROLLED STUDY; CYTOTOXICITY; ELECTRIC RESISTANCE; FLUORESCENCE; GASTROINTESTINAL BARRIER; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; TRANSEPITHELIAL ELECTRICAL RESISTANCE; WESTERN BLOTTING;

CACO-2 MODEL; DETOXIFICATION; MARINE BIOTOXIN; MDCK-II; OKADAIC ACID; P-GLYCOPROTEIN;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CARCINOGENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTESTINES; MADIN DARBY CANINE KIDNEY CELLS; MARINE TOXINS; METABOLIC DETOXICATION, DRUG; MICE; MITOCHONDRIA; OKADAIC ACID; P-GLYCOPROTEIN; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

EID: 84892560661     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.12.019     Document Type: Article

References (38)

1. Agarwal S., Jain R., Pal D., Mitra A.K. Functional characterization of peptide transporters in MDCKII-MDR1 cell line as a model for oral absorption studies. International Journal of Pharmaceutics 2007, 332:147-152.
2. Aonuma S., Ushijima T., Nakayasu M., Shima H., Sugimura T., Nagao M. Mutation-Induction by okadaic acid, a protein phosphatase inhibitor, in CHL cells, but not in Salmonella typhimurium. Mutation Research 1991, 250:375-381.
3. Aune T., Espenes A., Aasen J.A., Quilliam M.A., Hess P., Larsen S. Study of possible combined toxic effects of azaspiracid-1 and okadaic acid in mice via the oral route. Toxicon 2012, 60:895-906.
4. Bock U., Kottke T., Gindorf C., Haltner E. Validation of the Caco-2 cell monolayer system for determining the permeability of drug substances according to the Biopharmaceutics Classification System (BCS) 2003, (24.09.2013). http://acrossbarriers.de/uploads/media/FCT02-I-0305_BCS.pdf.
5. Boulenc X., Bourrie M., Fabre I., Roque C., Joyeux H., Berger Y., Fabre G. Regulation of cytochrome-P450Ia1 gene-expression in a human intestinal-cell line, Caco-2. Journal of Pharmacology and Experimental Therapeutics 1992, 263:1471-1478.
6. Buesen R., Mock M., Seidel A., Jacob J., Lampen A. Interaction between metabolism and transport of benzo[a]pyrene and its metabolites in enterocytes. Toxicology and Applied Pharmacology 2002, 183:168-178.
7. Casarini L., Franchini A., Malagoli D., Ottaviani E. Evaluation of the effects of the marine toxin okadaic acid by using FETAX assay. Toxicology Letters 2007, 169:145-151.
8. Cerep In vitro drug absorption 2010, (24.09.2013). http://www.cerep.fr/Cerep/Users/pages/Downloads/Documents/Marketing/Pharmacology%20%26%20ADME/Application%20notes/2010%20In%20vitro%20drug%20absorption.pdf.
9. Cho M.J., Thompson D.P., Cramer C.T., Vidmar T.J., Scieszka J.F. The Madin Darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharmaceutical Research 1989, 6:71-77.
10. Delie F., Rubas W. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Critical Reviews in Therapeutic Drug Carrier Systems 1997, 14:221-286.
11. Dixit D., Zarate N., Liu L.W.C., Boreham D.R., Huizinga J.D. Interstitial cells of Cajal and adaptive relaxation in the mouse stomach. American Journal of Physiology: Gastrointestinal and Liver Physiology 2006, 291:G1129-G1136.
12. Ebert B., Seidel A., Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 2005, 26:1754-1763.
13. Ehlers A., Stempin S., Al-Hamwi R., Lampen A. Embryotoxic effects of the marine biotoxin okadaic acid on murine embryonic stem cells. Toxicon 2010, 55:855-863.
14. Ehlers A., Scholz J., These A., Hessel S., Preiss-Weigert A., Lampen A. Analysis of the passage of the marine biotoxin okadaic acid through an in vitro human gut barrier. Toxicology 2011, 279:196-202.
15. European Food Safety Authority (EFSA) Marine biotoxins in shellfish - okadaic acid and analogues - Scientific Opinion of the Panel on Contaminants in the Food chain. The EFSA Journal 2008, 1-62.
16. Fessard V., Grosse Y., PfohlLeszkowicz A., PuiseuxDao S. Okadaic acid treatment induces DNA adduct formation in BHK21 C13 fibroblasts and HESV keratinocytes. Mutation Research-Environmental Mutagenesis and Related Subjects 1996, 361:133-141.
17. Guo F.J., An T.Y., Rein K.S. The algal hepatoxoxin okadaic acid is a substrate for human cytochromes CYP3A4 and CYP3A5. Toxicon 2010, 55:325-332.
18. Hunter J., Jepson M.A., Tsuruo T., Simmons N.L., Hirst B.H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. Journal of Biological Chemistry 1993, 268:14991-14997.
19. Irvine J.D., Takahashi L., Lockhart K., Cheong J., Tolan J.W., Selick H.E., Grove J.R. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. Journal of Pharmaceutical Science 1999, 88:28-33.
20. Ito E., Yasumoto T., Takai A., Imanishi S., Harada K. Investigation of the distribution and excretion of okadaic acid in mice using immunostaining method. Toxicon 2002, 40:159-165.
21. Kawai Y., Yamaguchi T., Yoden T., Hanada M., Miyake M. Effect of protein phosphatase inhibitors on the development of mouse embryos: protein phosphorylation is involved in the E-cadherin distribution in mouse two-cell embryos. Biological and Pharmaceutical Bulletin 2002, 25:179-183.
22. Kittler K., Preiss-Weigert A., These A. Identification strategy using combined mass spectrometric techniques for elucidation of phase I and phase II in vitro metabolites of lipophilic marine biotoxins. Analytical Chemistry 2010, 82:9329-9335.
23. Lampen A., Bader A., Bestmann T., Winkler M., Witte L., Borlak J.T. Catalytic activities, protein- and mRNA-expression of cytochrome P450 isoenzymes in intestinal cell lines. Xenobiotica 1998, 28:429-441.
24. Le Hegarat L., Fessard V., Poul J.M., Dragacci S., Sanders P. Marine toxin okadaic acid induces aneuploidy in CHO-K1 cells in presence of rat liver postmitochondrial fraction, revealed by cytokinesis-block micronucleus assay coupled to FISH. Environmental Toxicology 2004, 19:123-128.
25. Le Hegarat L., Jacquin A.G., Bazin E., Fessard V. Genotoxicity of the marine toxin okadaic acid, in human caco-2 cells and in mice gut cells. Environmental Toxicology 2006, 21:55-64.
26. Matias W.G., Creppy E.E. Transplacental passage of [3H]-okadaic acid in pregnant mice measured by radioactivity and high-performance liquid chromatography. Human and Experimental Toxicology 1996, 15:226-230.
27. Matias W.G., Traore A., Creppy E.E. Variations in the distribution of okadaic acid in organs and biological fluids of mice related to diarrhoeic syndrome. Human and Experimental Toxicology 1999, 18:345-350.
28. Nishina Y., Sumi T., Iwai S.A., Nishimune Y. Effects of protein phosphatase inhibition by okadaic acid on the differentiation of F9 embryonal carcinoma cells. Experimental Cell Research 1995, 217:288-293.
29. Sharom F.J. The P-glycoprotein multidrug transporter. Essays in Biochemistry 2011, 50:161-178.
30. Siccardi D., Kandalaft L.E., Gumbleton M., McGuigan C. Stereoselective and concentration-dependent polarized epithelial permeability of a series of phosphoramidate triester prodrugs of d4T: an in vitro study in Caco-2 and Madin-Darby canine kidney cell monolayers. Journal of Pharmacology and Experimental Therapeutics 2003, 307:1112-1119.
31. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Analytical Biochemistry 1985, 150:76-85.
32. Stevenson B.R., Anderson J.M., Goodenough D.A., Mooseker M.S. Tight junction structure and ZO-1 content are identical in two strains of Madin-Darby canine kidney cells which differ in transepithelial resistance. Journal of Cell Biology 1988, 107:2401-2408.
33. Suganuma M., Fujiki H., Suguri H., Yoshizawa S., Hirota M., Nakayasu M., Ojika M., Wakamatsu K., Yamada K., Sugimura T. Okadaic acid - an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:1768-1771.
34. Suganuma M., Tatematsu M., Yatsunami J., Yoshizawa S., Okabe S., Uemura D., Fujiki H. An alternative theory of tissue-specificity by tumor promotion of okadaic acid in glandular stomach of SD rats. Carcinogenesis 1992, 13:1841-1845.
35. These A., Scholz J., Preiss-Weigert A. Sensitive method for the determination of lipophilic marine biotoxins in extracts of mussels and processed shellfish by high-performance liquid chromatography-tandem mass spectrometry based on enrichment by solid-phase extraction. Journal of Chromatography A 2009, 1216:4529-4538.
36. Tohda H., Nagao M., Sugimura T., Oikawa A. Okadaic acid, a protein phosphatase inhibitor, induces sister-chromatid exchanges depending on the presence of bromodeoxyuridine. Mutation Research 1993, 289:275-280.
37. Valdiglesias V., Laffon B., Pasaro E., Mendez J. Evaluation of okadaic acid-induced genotoxicity in human cells using the micronucleus test and gammaH2AX analysis. Journal of Toxicology and Environmental Health A 2011, 74:980-992.
38. van der Holt B., Lowenberg B., Burnett A.K., Knauf W.U., Shepherd J., Piccaluga P.P., Ossenkoppele G.J., Verhoef G.E., Ferrant A., Crump M., Selleslag D., Theobald M., Fey M.F., Vellenga E., Dugan M., Sonneveld P. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005, 106:2646-2654.